Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2020-04-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（陈敏）
Regulatory Filings
2020-04-28 Chinese
2019年度内部控制审计报告
Regulatory Filings
2020-04-28 Chinese
关于选举第十届监事会职工监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of a new employee supervisor to the company's supervisory board (监事会). It includes details about the election process, the term, and a brief resume of the elected individual. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content is about board/management changes specifically related to the supervisory board. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management election, not a report or announcement of a report.
2020-04-28 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司发行股份购买资产并募集配套资金暨关联交易之2019年度独立财务顾问持续督导意见
Audit Report / Information Classification · 95% confidence The document is titled as an independent financial advisor's continuous supervision opinion for a transaction involving issuance of shares to purchase assets and raising supporting funds, related to a major asset restructuring. It includes detailed sections on the transaction overview, implementation status, fulfillment of commitments, performance forecasts and achievement, management discussion and analysis, company governance, and differences from the announced restructuring plan. The document contains substantive financial data, audit reports, and detailed analysis related to the transaction and company performance. It is not a full annual report but a specialized report focused on the asset purchase and fundraising transaction with associated financial and governance analysis. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on a specific transaction and its financial implications, not a full annual report or other category. The document length (6491 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2019
2020-04-28 Chinese
独立董事关于计提资产减值损失的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the company's decision to recognize an asset impairment loss. It references compliance with corporate governance standards, accounting principles, and company bylaws. The content is focused on the approval and legitimacy of the impairment loss decision rather than presenting full financial statements or detailed audit results. The document length is short (571 characters), and it does not contain comprehensive financial data or audit findings. It is not a full audit report but rather an independent directors' opinion on a specific accounting matter. This fits best under Audit Report / Information (AR), which includes standalone audit-related opinions and accounting principle applications, excluding full annual reports. FY 2023
2020-04-28 Chinese
九届十六次监事会会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 16th meeting of the 9th Supervisory Board of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes approvals of various reports such as the 2019 Annual Report, 2019 Annual Financial Statements, 2020 Q1 Report, and other internal control and financial budget reports. It also includes nominations for the 10th Supervisory Board members. The document contains detailed content of the meeting decisions, voting results, and references to the full reports available on the Shanghai Stock Exchange website. The document length is 2834 characters, which is relatively short but contains substantive content of the meeting resolutions and approvals, not just an announcement of report publication. The document is not a full annual report itself but a supervisory board meeting resolution announcement that includes approval of the annual report and other reports. This type of document fits best under the category of Board/Management Information (MANG), as it announces board/supervisory board meeting resolutions and management decisions including nominations and approvals of financial reports, rather than the reports themselves or their publication announcements.
2020-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.